Literature DB >> 19870270

EXPERIMENTAL TYPE III PNEUMOCOCCUS PNEUMONIA IN MONKEYS : II. TREATMENT WITH AN ENZYME WHICH DECOMPOSES THE SPECIFIC CAPSULAR POLYSACCHARIDE OF PNEUMOCOCCUS TYPE III.

T Francis1, E E Terrell, R Dubos, O T Avery.   

Abstract

The effects of specific enzyme therapy upon experimental Type III pneumococcus pneumonia in monkeys were studied by comparing the course and outcome of the disease in treated animals with that in animals which received no therapeutic aid. Enzyme treatment was found to exert a distinctly favorable influence upon the experimental pneumonia. Treatment was followed by cessation of spread of the pneumonic lesion, sterilization of the blood, and early recovery, except in animals in which the severity of the disease was extreme. While in the untreated animals a high incidence of empyema and pericarditis was observed, suppurative sequelae were apparently prevented by adequate enzyme therapy. The limitations of the therapeutic action of the specific enzyme in the presence of marked depression of the cellular reaction in infected animals are again emphasized.

Entities:  

Year:  1934        PMID: 19870270      PMCID: PMC2132365          DOI: 10.1084/jem.59.5.641

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  6 in total

1.  EXPERIMENTAL TYPE III PNEUMOCOCCUS PNEUMONIA IN MONKEYS : I. PRODUCTION AND CLINICAL COURSE.

Authors:  T Francis; E E Terrell
Journal:  J Exp Med       Date:  1934-04-30       Impact factor: 14.307

2.  DECOMPOSITION OF THE CAPSULAR POLYSACCHARIDE OF PNEUMOCOCCUS TYPE III BY A BACTERIAL ENZYME.

Authors:  R Dubos; O T Avery
Journal:  J Exp Med       Date:  1931-06-30       Impact factor: 14.307

3.  THE ACTION OF A SPECIFIC ENZYME UPON THE DERMAL INFECTION OF RABBITS WITH TYPE III PNEUMOCOCCUS.

Authors:  K Goodner; R Dubos; O T Avery
Journal:  J Exp Med       Date:  1932-02-29       Impact factor: 14.307

4.  STUDIES ON THE QUANTITATIVE ACTION OF A SPECIFIC ENZYME IN TYPE III PNEUMOCOCCUS DERMAL INFECTION IN RABBITS.

Authors:  K Goodner; R Dubos
Journal:  J Exp Med       Date:  1932-09-30       Impact factor: 14.307

5.  THE PROTECTIVE ACTION OF A SPECIFIC ENZYME AGAINST TYPE III PNEUMOCOCCUS INFECTION IN MICE.

Authors:  O T Avery; R Dubos
Journal:  J Exp Med       Date:  1931-06-30       Impact factor: 14.307

6.  FACTORS AFFECTING THE YIELD OF SPECIFIC ENZYME IN CULTURES OF THE BACILLUS DECOMPOSING THE CAPSULAR POLYSACCHARIDE OF TYPE III PNEUMOCOCCUS.

Authors:  R Dubos
Journal:  J Exp Med       Date:  1932-02-29       Impact factor: 14.307

  6 in total
  8 in total

1.  Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection.

Authors:  David Negus; Julia Vipond; Graham J Hatch; Emma L Rayner; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Administration of capsule-selective endosialidase E minimizes upregulation of organ gene expression induced by experimental systemic infection with Escherichia coli K1.

Authors:  Andrea Zelmer; Melissa J Martin; Ozan Gundogdu; George Birchenough; Rebecca Lever; Brendan W Wren; J Paul Luzio; Peter W Taylor
Journal:  Microbiology (Reading)       Date:  2010-04-15       Impact factor: 2.777

Review 3.  The past, present, and future of enzyme-based therapies.

Authors:  Jennifer N Hennigan; Michael D Lynch
Journal:  Drug Discov Today       Date:  2021-09-16       Impact factor: 7.851

Review 4.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

5.  The T7-related Pseudomonas putida phage φ15 displays virion-associated biofilm degradation properties.

Authors:  Anneleen Cornelissen; Pieter-Jan Ceyssens; Jeroen T'Syen; Helena Van Praet; Jean-Paul Noben; Olga V Shaburova; Victor N Krylov; Guido Volckaert; Rob Lavigne
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

6.  The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages.

Authors:  James J Bull; Jason J Gill
Journal:  Front Microbiol       Date:  2014-11-18       Impact factor: 5.640

Review 7.  Bacteriophages and Their Immunological Applications against Infectious Threats.

Authors:  Elena Criscuolo; Sara Spadini; Jacopo Lamanna; Mattia Ferro; Roberto Burioni
Journal:  J Immunol Res       Date:  2017-04-16       Impact factor: 4.818

8.  Characterisation of Bacteriophage-Encoded Depolymerases Selective for Key Klebsiella pneumoniae Capsular Exopolysaccharides.

Authors:  George Blundell-Hunter; Mark C Enright; David Negus; Matthew J Dorman; Gemma E Beecham; Derek J Pickard; Phitchayapak Wintachai; Supayang P Voravuthikunchai; Nicholas R Thomson; Peter W Taylor
Journal:  Front Cell Infect Microbiol       Date:  2021-06-18       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.